Skip to main content
NCBI home page
Gut logoLink to Gut
. 1984 Jun;25(6):673–681. doi: 10.1136/gut.25.6.673

Hepatotoxicity to sodium valproate: a review.

P R Powell-Jackson, J M Tredger, R Williams
PMCID: PMC1432377  PMID: 6428980

Full text

PDF
673

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Addison G. M., Gordon N. S. Sodium valproate and acute hepatic failure. Dev Med Child Neurol. 1980 Apr;22(2):248–249. doi: 10.1111/j.1469-8749.1980.tb04339.x. [DOI] [PubMed] [Google Scholar]
  2. Bates E. M. A consumer's view of the Australian experience in health insurance. Lancet. 1980 Jul 5;2(8184):26–28. doi: 10.1016/s0140-6736(80)92900-1. [DOI] [PubMed] [Google Scholar]
  3. Bellmann M. H., Ross E. M. Side effects of sodium valproate. Br Med J. 1977 Jun 25;1(6077):1662–1662. doi: 10.1136/bmj.1.6077.1662-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Beran R. G., Read T., Reid M., Rischbieth R. H., Sansom L., Schapel G. J., Stanley P. E. Individualized patient assessment in the treatment of epilepsy with sodium valproate. Epilepsia. 1980 Aug;21(4):379–386. doi: 10.1111/j.1528-1157.1980.tb04085.x. [DOI] [PubMed] [Google Scholar]
  5. Black M., Mitchell J. R., Zimmerman H. J., Ishak K. G., Epler G. R. Isoniazid-associated hepatitis in 114 patients. Gastroenterology. 1975 Aug;69(2):289–302. [PubMed] [Google Scholar]
  6. Bressler R., Corredor C., Brendel K. Hypoglycin and hypoglycin-like compounds. Pharmacol Rev. 1969 Jun;21(2):105–130. [PubMed] [Google Scholar]
  7. Chadwick D. W., Cumming W. J., Livingstone I., Cartlidge N. E. Acute intoxication with sodium valproate. Ann Neurol. 1979 Dec;6(6):552–553. doi: 10.1002/ana.410060616. [DOI] [PubMed] [Google Scholar]
  8. Coude F. X., Rabier D., Cathelineau L., Grimber G., Parvy P., Kamoun P. P. A mechanism for valproate-induced hyperammonemia. Pediatr Res. 1981 Jun;15(6):974–975. doi: 10.1203/00006450-198106000-00020. [DOI] [PubMed] [Google Scholar]
  9. Coulter D. L., Allen R. J. Hyperammonemia with valproic acid therapy. J Pediatr. 1981 Aug;99(2):317–319. doi: 10.1016/s0022-3476(81)80489-1. [DOI] [PubMed] [Google Scholar]
  10. Coulter D. L., Allen R. J. Secondary hyperammonaemia: a possible mechanism for valproate encephalopathy. Lancet. 1980 Jun 14;1(8181):1310–1311. doi: 10.1016/s0140-6736(80)91773-0. [DOI] [PubMed] [Google Scholar]
  11. Coulter D. L., Wu H., Allen R. J. Valproic acid therapy in childhood epilepsy. JAMA. 1980 Aug 22;244(8):785–788. [PubMed] [Google Scholar]
  12. Dodson W. E., Tasch V. Pharmacology of valproic acid in children with severe epilepsy: clearance and hepatotoxicity. Neurology. 1981 Aug;31(8):1047–1050. doi: 10.1212/wnl.31.8.1047. [DOI] [PubMed] [Google Scholar]
  13. Donat J. F., Bocchini J. A., Jr, Gonzalez E., Schwendimann R. N. Valproic acid and fatal hepatitis. Neurology. 1979 Feb;29(2):273–274. [PubMed] [Google Scholar]
  14. Ehrenthal W., Rochel M. Kontrolle der Valproinsäure-Therapie durch Serumspiegelbestimmungen mit HPLC oder EMIT und durch gleichzeitige Bestimmung klinisch-chemischer Parameter. Arzneimittelforschung. 1982;32(4):449–452. [PubMed] [Google Scholar]
  15. Gastaut H., Noel P. A case of fatal toxic hepatitis: recommendations for the administration of sodium valproate. Epilepsia. 1981 Dec;22(6):711–713. doi: 10.1111/j.1528-1157.1981.tb04145.x. [DOI] [PubMed] [Google Scholar]
  16. Glasgow A. M., Chase H. P. Production of the features of Reye's syndrome in rats with 4-pentenoic acid. Pediatr Res. 1975 Mar;9(3):133–138. doi: 10.1203/00006450-197503000-00005. [DOI] [PubMed] [Google Scholar]
  17. Goldman M., Vlahcevic Z. R., Schwartz C. C., Gustafsson J., Swell L. Bile acid metabolism in cirrhosis. VIII. Quantitative evaluation of bile acid synthesis from [7 beta-3H]7 alpha-hydroxycholesterol and [G-3H]26-hydroxycholesterol. Hepatology. 1982 Jan-Feb;2(1):59–66. doi: 10.1002/hep.1840020110. [DOI] [PubMed] [Google Scholar]
  18. Goudie B. M., Birnie G. F., Watkinson G., MacSween R. N., Kissen L. H., Cunningham N. E. Jaundice associated with the use of benoxaprofen. Lancet. 1982 Apr 24;1(8278):959–959. doi: 10.1016/s0140-6736(82)91953-5. [DOI] [PubMed] [Google Scholar]
  19. Iivanainen M., Himberg J. J. Valproate and clonazepam in the treatment of severe progressive myoclonus epilepsy. Arch Neurol. 1982 Apr;39(4):236–238. doi: 10.1001/archneur.1982.00510160042008. [DOI] [PubMed] [Google Scholar]
  20. Jacobi G., Thorbeck R., Ritz A., Janssen W., Schmidts H. L. Fatal hepatotoxicity in child on phenobarbitone and sodium valproate. Lancet. 1980 Mar 29;1(8170):712–713. [PubMed] [Google Scholar]
  21. Keene D. L., Humphreys P., Carpenter B., Fletcher J. P. Valproic acid producing a Reye-like syndrome. Can J Neurol Sci. 1982 Nov;9(4):435–437. doi: 10.1017/s0317167100044358. [DOI] [PubMed] [Google Scholar]
  22. Le Bihan G., Bourreille J., Sampson M., Leroy J., Szekely A. M., Coquerel A. Fatal hepatic failure and sodium valproate. Lancet. 1980 Dec 13;2(8207):1298–1299. doi: 10.1016/s0140-6736(80)92359-4. [DOI] [PubMed] [Google Scholar]
  23. Lee K., Melchior J. C. Sodium valproate versus phenobarbital in the prophylactic treatment of febrile convulsions in childhood. Eur J Pediatr. 1981 Oct;137(2):151–153. doi: 10.1007/BF00441308. [DOI] [PubMed] [Google Scholar]
  24. Lewis J. H., Zimmerman H. J., Garrett C. T., Rosenberg E. Valproate-induced hepatic steatogenesis in rats. Hepatology. 1982 Nov-Dec;2(6):870–873. doi: 10.1002/hep.1840020622. [DOI] [PubMed] [Google Scholar]
  25. Maddrey W. C., Boitnott J. K. Isoniazid hepatitis. Ann Intern Med. 1973 Jul;79(1):1–12. doi: 10.7326/0003-4819-79-1-1. [DOI] [PubMed] [Google Scholar]
  26. Mattson R. H., Cramer J. A., Williamson P. D., Novelly R. A. Valproic acid in epilepsy: clinical and pharmacological effects. Ann Neurol. 1978 Jan;3(1):20–25. doi: 10.1002/ana.410030105. [DOI] [PubMed] [Google Scholar]
  27. Minagawa K., Miura H. Phenobarbital, primidone and sodium valproate in the prophylaxis of febrile convulsions. Brain Dev. 1981;3(4):385–393. doi: 10.1016/s0387-7604(81)80067-8. [DOI] [PubMed] [Google Scholar]
  28. Monnet P., David M., Philippe N., Dechavanne M., Floret D., Renaud H., Trezeciak M. C., Brazier J. L., Bourdillon D. Altérations de l'hémostase lors des traitements au dipropylacétate de Sodium (Dépakine) (R). Pediatrie. 1979 Sep;34(6):603–620. [PubMed] [Google Scholar]
  29. Murphy J. V., Marquardt K. Asymptomatic hyperammonemia in patients receiving valproic acid. Arch Neurol. 1982 Sep;39(9):591–592. doi: 10.1001/archneur.1982.00510210061016. [DOI] [PubMed] [Google Scholar]
  30. Pisarski W., Majkowski J., Lysakowska-Sernicka K., Bilińska-Nigot B. Sodium dipropylacetate (Vupral Polfa) in therapy of resistant epilepsy. Monogr Neural Sci. 1980;5:131–136. doi: 10.1159/000387495. [DOI] [PubMed] [Google Scholar]
  31. Rawat S., Borkowski W. J., Jr, Swick H. M. Valproic acid and secondary hyperammonemia. Neurology. 1981 Sep;31(9):1173–1174. doi: 10.1212/wnl.31.9.1173. [DOI] [PubMed] [Google Scholar]
  32. Redenbaugh J. E., Sato S., Penry J. K., Dreifuss F. E., Kupferberg H. J. Sodium valproate: pharmacokinetics and effectivensss in treating intractable seizures. Neurology. 1980 Jan;30(1):1–6. doi: 10.1212/wnl.30.1.1. [DOI] [PubMed] [Google Scholar]
  33. Richens A., Ahmad S. Controlled trial of sodium valproate in severe epilepsy. Br Med J. 1975 Nov 1;4(5991):255–256. doi: 10.1136/bmj.4.5991.255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Rodman J. S., Deutsch D. J., Gutman S. I. Methyldopa Hepatitis. A report of six cases and review of the literature. Am J Med. 1976 Jun;60(7):941–948. doi: 10.1016/0002-9343(76)90564-7. [DOI] [PubMed] [Google Scholar]
  35. Sato S., White B. G., Penry J. K., Dreifuss F. E., Sackellares J. C., Kupferberg H. J. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology. 1982 Feb;32(2):157–163. doi: 10.1212/wnl.32.2.157. [DOI] [PubMed] [Google Scholar]
  36. Schneble H. Labor-Parameter unter Valproat-Therapie. Nervenarzt. 1982 Dec;53(12):684–690. [PubMed] [Google Scholar]
  37. Sherard E. S., Jr, Steiman G. S., Couri D. Treatment of childhood epilepsy with valproic acid: results of the first 100 patients in a 6-month trial. Neurology. 1980 Jan;30(1):31–35. doi: 10.1212/wnl.30.1.31. [DOI] [PubMed] [Google Scholar]
  38. Suchy F. J., Balistreri W. F., Buchino J. J., Sondheimer J. M., Bates S. R., Kearns G. L., Stull J. D., Bove K. E. Acute hepatic failure associated with the use of sodium valproate. N Engl J Med. 1979 Apr 26;300(17):962–966. doi: 10.1056/NEJM197904263001706. [DOI] [PubMed] [Google Scholar]
  39. Taggart H. M., Alderdice J. M. Fatal cholestatic jaundice in elderly patients taking benoxaprofen. Br Med J (Clin Res Ed) 1982 May 8;284(6326):1372–1372. doi: 10.1136/bmj.284.6326.1372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Tripp J. H., Hargreaves T., Anthony P. P., Searle J. F., Miller P., Leonard J. V., Patrick A. D., Oberholzer V. G. Sodium valproate and ornithine carbamyl transferase deficiency. Lancet. 1981 May 23;1(8230):1165–1166. doi: 10.1016/s0140-6736(81)92338-2. [DOI] [PubMed] [Google Scholar]
  41. Turnbull D. M., Rawlins M. D., Weightman D., Chadwick D. W. A comparison of phenytoin and valproate in previously untreated adult epileptic patients. J Neurol Neurosurg Psychiatry. 1982 Jan;45(1):55–59. doi: 10.1136/jnnp.45.1.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Vanasse M., David P., Geoffroy G., Larbrisseau A. Toxic reactions with valproic acid therapy. Neurology. 1981 May;31(5):644–644. doi: 10.1212/wnl.31.5.644-a. [DOI] [PubMed] [Google Scholar]
  43. Ware S., Millward-Sadler G. H. Acute liver disease associated with sodium valproate. Lancet. 1980 Nov 22;2(8204):1110–1113. doi: 10.1016/s0140-6736(80)92543-x. [DOI] [PubMed] [Google Scholar]
  44. Young R. S., Bergman I., Gang D. L., Richardson E. P., Jr Fatal Reye-like syndrome associated with valproic acid. Ann Neurol. 1980 Apr;7(4):389–389. doi: 10.1002/ana.410070423. [DOI] [PubMed] [Google Scholar]
  45. Zafrani E. S., Berthelot P. Sodium valproate in the induction of unusual hepatotoxicity. Hepatology. 1982 Sep-Oct;2(5):648–649. doi: 10.1002/hep.1840020520. [DOI] [PubMed] [Google Scholar]
  46. Zaret B. S., Beckner R. R., Marini A. M., Wagle W., Passarelli C. Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction. Neurology. 1982 Feb;32(2):206–208. doi: 10.1212/wnl.32.2.206. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES